Basiliximab is a monoclonal anti-C25 antibody (interleukin-2 receptor alpha subunit) used as immunosuppressive therapy in kidney transplant patients. A recombinant chimeric (murine/human) monoclonal antibody (IgG1k) that functions as an immunosuppressive agent, specifically binding to and blocking the interleukin-2 receptor a-chain (IL-2R alpha, also known as CD25 antigen) on the surface of activated T-lymphocytes.
- Mechanism
- Curator reviewed
Basiliximab binds with high-affinity to the alpha-subunit (CD25) of the high-affinity IL-2 receptor. This inhibits IL-2 binding, which inhibits T-cell activation and prevents the body from mounting an immune response against the foreign kidney.
- Primary indication
- For prophylactic treatment of kidney transplant rejectionCurator reviewed · 1 structured indication
- Formula / weight
- C6378H9844N1698O1997S48 · 143801.3 Da
- First approval
- Canada, 2000 · United States, 1998 · European Union, 2016
- Code names
- CHI-621 · SDZ-CHI-621
- Brand names
Resolves to
What you can answer from here — as of July 17, 2026
Which drugs share a target with Basiliximab, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account